Synaptixbio
Developing gene-silencing therapies for children with rare leukodystrophies, including H-ABC
Highlights
- New on EvolcAdded 2026-11-12
About Synaptixbio
SynaptixBio develops antisense oligonucleotide therapies intended to silence the mutated TUBB4A gene and treat leukodystrophies, including H-ABC and isolated hypomyelination. It is also developing a pipeline for related neurodegenerative disorders.
The company focuses on therapies for patients with rare brain disorders. Its team includes expertise in drug research, clinical development, regulatory affairs and corporate development.
Founded in 2021, SynaptixBio is headquartered in Oxford, United Kingdom. It holds FDA Rare Pediatric Drug and Orphan Drug designations for H-ABC and isolated hypomyelination.
Product: Antisense oligonucleotide gene-silencing therapies for TUBB4A-related leukodystrophies and other neurodegenerative disorders.
Jobs at Synaptixbio
Leadership
- Bent Jakobsen · Executive Director and FounderSource: company website
- Michelle Teng · Chief Scientific Officer, Executive Director and Co-FounderSource: company website
- Dan Williams · Chief Executive Officer, Executive Director and Co-founderSource: company website
More biotech & pharma companies
Syngensys
Synthetic gene promoters and custom genetic components for gene and cell therapy developers and biomanufacturersNew on EvolcSynthace
Experiment design, lab automation and AI-ready data software for drug discovery and life science R&D teamsT-Cypher Bio
Develops immune engager drugs for cancer and autoimmune diseases, built on proprietary wet-lab and computational platformsTarget Healthcare
Pharmaceutical manufacturer and wholesaler supplying medicines to pharmacies, hospitals and other healthcare providersTaw Pharma
Marketing authorisation holder providing UK and EU regulatory support for medicinal product licence applicationsTay Therapeutics
Develops targeted small-molecule therapies for patients with serious diseases and high unmet medical needNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.